Foreign investors are continuing to sell off from the domestic markets. However, it is not that foreign investors are keeping a distance from the Indian markets. There are many companies and sectors where FIIs have made purchases in the last quarter. One of these is the pharma sector. If we look at the data of the September quarter, FIIs' holding in 12 companies out of the companies included in the Nifty Pharma Index has increased in the second quarter. In some of these companies, FIIs are continuously buying, while in some companies they have increased their holding once again after reducing their stake.

FII holding in Zydus Lifesciences

company has seen a sharp increase during the September quarter. According to the data, FII holding in the company has increased to 7.52 percent by the end of September quarter, which was at 5.59 percent by the end of June quarter. The stock has given a return of 75 percent in the last one year. However, the stock has fallen 13 percent in 3 months. Glenmark Pharma FIIs have bought Glenmark Pharma in September. According to the data at the end of the September quarter, the share of FIIs in the company has increased from 20.98 percent to 23.05 percent as compared to the June quarter. The special thing is that till the June quarter, FIIs were selling the stock and by the end of the first quarter, the share of FIIs was at the lowest levels in the last one year, although FII holding has increased once again in the September quarter. The stock has given a return of 97 percent so far in the year 2024. Lupin The holding of FIIs in Lupin is continuously increasing. By the end of the September quarter, the FII share in the company has increased to 21.5 percent. Which was 19.32 percent by the end of June 2024, 18.29 percent by the end of March 2024, 16.11 percent by the end of December 2023. The stock has increased 57 percent so far in the year 2024, while the stock has fallen by about 5 percent in a month. And in which companies did FII increase its stake - If we look at the FII holding in the second quarter compared to the first quarter, the holding in Laurel Lab increased from 25.67 percent to 26.08 percent, in Biocon it increased from 5.9 percent to 5.93 percent. Holding in Torrent Pharma increased from 14.22% to 14.46%, Natco Pharma from 17.45% to 17.51%, Cipla from 27.82% to 28.8%, Divi's Lab from 16.16% to 17.25%, Mankind from 11.58% to 12.37%, Sun Pharma from 17.23% to 18.01% and Alkem Lab from 8.69% to 9.02%.